WO2006087233A3 - Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells - Google Patents

Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells Download PDF

Info

Publication number
WO2006087233A3
WO2006087233A3 PCT/EP2006/001552 EP2006001552W WO2006087233A3 WO 2006087233 A3 WO2006087233 A3 WO 2006087233A3 EP 2006001552 W EP2006001552 W EP 2006001552W WO 2006087233 A3 WO2006087233 A3 WO 2006087233A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
mammal
prominin
present
extracellular membrane
Prior art date
Application number
PCT/EP2006/001552
Other languages
French (fr)
Other versions
WO2006087233A2 (en
Inventor
Denis Corbeil
Wieland B Huttner
Anne-Marie Marzesco
Original Assignee
Max Planck Gesellschaft
Denis Corbeil
Wieland B Huttner
Anne-Marie Marzesco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Denis Corbeil, Wieland B Huttner, Anne-Marie Marzesco filed Critical Max Planck Gesellschaft
Publication of WO2006087233A2 publication Critical patent/WO2006087233A2/en
Publication of WO2006087233A3 publication Critical patent/WO2006087233A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to an extracellular membrane particle carrying integrated into the membrane prominin-1 molecules. In accordance with the present invention, theses particles also referred to as prominin-1 -containing membrane particles. The membrane particles according to the present invention are distinct from exosomes. The invention in a further aspect relates to a method of diagnosing an epithelial cancer or a hematopoietic disease in a mammal comprising assessing in a body fluid of said mammal for the presence of the extracellular membrane particle of the invention wherein a decreased level of said extracellular membrane particles as compared to a control value is indicative of the presence of an epithelial cancer or a hematopoietic disease. Alternatively, an increased level of said particles is indicative of the presence of such a disease in a mammal. Additionally, the present invention relates to a method of prognosing a solid tumor in a mammal, comprising determining the change in the number of the particles of the invention in a body fluid of said mammal over time. Finally, the present invention relates to a method of diagnosing a degeneration of the retina in a mammal or a predisposition thereto comprising assessing for the presence of prominin-1 on the surface of the particles of the invention in a body fluid from said mammal wherein the absence of said particles or a reduced amount of prominin-1 on the surface of said particles in comparison to a control is indicative of degeneration of the retina or a predisposition thereto.
PCT/EP2006/001552 2005-02-21 2006-02-21 Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells WO2006087233A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003687.0 2005-02-21
EP05003687 2005-02-21

Publications (2)

Publication Number Publication Date
WO2006087233A2 WO2006087233A2 (en) 2006-08-24
WO2006087233A3 true WO2006087233A3 (en) 2006-11-02

Family

ID=36676697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/001552 WO2006087233A2 (en) 2005-02-21 2006-02-21 Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells

Country Status (1)

Country Link
WO (1) WO2006087233A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP7075594B2 (en) 2015-11-18 2022-05-26 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド Extracellular vesicles of nerve cells

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2176665B1 (en) 2007-08-16 2016-03-02 The Royal Institution for the Advancement of Learning / McGill University Tumor cell-derived microvesicles
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CA2732108A1 (en) 2008-07-28 2010-02-04 Children's Medical Center Corporation Prominin-1 peptide fragments and uses thereof
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
JP6046493B2 (en) 2010-01-27 2016-12-14 チルドレンズ メディカル センター コーポレーション Proangin-1 angiogenesis-promoting fragments and uses thereof
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20150093447A1 (en) * 2012-03-23 2015-04-02 Neostem, Inc. Stem cell identification and purification method
BR112014024541A2 (en) * 2012-04-03 2017-08-08 Reneuron Ltd stem cell microparticles
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORBEIL D ET AL: "Prominin: a story of cholesterol, plasma membrane protrusions and human pathology.", TRAFFIC (COPENHAGEN, DENMARK) FEB 2001, vol. 2, no. 2, February 2001 (2001-02-01), pages 82 - 91, XP002391918, ISSN: 1398-9219 *
MARZESCO ANNE-MARIE ET AL: "Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells.", JOURNAL OF CELL SCIENCE. 1 JUL 2005, vol. 118, no. Pt 13, 1 July 2005 (2005-07-01), pages 2849 - 2858, XP002391919, ISSN: 0021-9533 *
RICHARDSON GAVIN D ET AL: "CD133, a novel marker for human prostatic epithelial stem cells", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 117, no. 16, 15 July 2004 (2004-07-15), pages 3539 - 3545, XP002354680, ISSN: 0021-9533 *
YIN A H ET AL: "AC133, a novel marker for human hematopoietic stem and progenitor cells", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 90, no. 12, 15 December 1997 (1997-12-15), pages 5002 - 5012, XP002264586, ISSN: 0006-4971 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP7075594B2 (en) 2015-11-18 2022-05-26 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド Extracellular vesicles of nerve cells

Also Published As

Publication number Publication date
WO2006087233A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006087233A3 (en) Release of extracellular membrane particles carrying the stem cell marker prominin-1 (cd133) from neural progenitors and other epithelial cells
WO2007103541A3 (en) Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007079250A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2007056622A3 (en) Method for discriminating platelets from red blood cells
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007011856A3 (en) Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
WO2010083252A3 (en) Ratio based biomarkers and methods of use thereof
WO2008002745A3 (en) Method for a fully automated monoclonal antibody-based extended differential
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
Todenhöfer et al. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer
WO2007027905A3 (en) Human renal stem cells
Boussafir et al. Petrographical and geochemical study of modern lacustrine sedimentary organic matter (Lagoa do Caçò, Maranão, Brazil): Relationship between early diagenesis, organic sedimentation and lacustrine filling
WO2007012811A9 (en) Prostate stem cell markers
WO2012021841A3 (en) Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2008037700A3 (en) Methods for breast cancer prognosis
EP3185013A3 (en) Biomarkers for determining an allograft tolerant phenotype
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
Lenz et al. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
Yu et al. Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma
WO2007079301A3 (en) Method of diagnosing a body weight condition or predisposition in an animal
Chen et al. Serum lipase on postoperative day one is a strong predictor of clinically relevant pancreatic fistula after pancreaticoduodenectomy: a retrospective cohort
Lin et al. A clinicopathological study of the significance of the proportion of choroid morphology in chordoid meningioma
WO2006026714A8 (en) Diagnosis and prognosis of cancer based on telomere length as measured on cytological specimens
WO2010035259A3 (en) Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06707127

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6707127

Country of ref document: EP